About Society


  • The History of Medical Oncology Society

    The application for foundation of Medical Oncology Society has been done in 5.8.1996 in Istanbul, by seven founding members Bülent Berkarda, Metin Aran, Haluk Onat, Süheyla Serdengeçti, Necdet Üskent, Erkan Topuz and Evin Büyükünal. The foundation aims of the Medical Oncology Society is to defend the rights of medical oncologists, to establish interactions with their foreign addressees, to organize and control the medical oncology education and to organize postgraduate courses, meetings and congresses. Together with the acceptance of the regulations which have been formed in accordance with these purposes, its foundation has been completed officially in 15.3.1997. All of thirty medical oncologists in Turkey have become members of the society during the foundation. During the first four periods, the president of the society was Bülent Berkarda. During this period the Medical Oncology Society has organized several courses, provided projects and support for foreign education and have been among the organizers of the National Cancer Congress which has been organized in 2001.

    Beginning from the foundation of the society, a total of 10 ordinary general meetings have been held biyearly and three extraordinary general meetings have been held for taking important decisions that require changes in regulations. The items which would provide continuity and representation such as to restrict the duration of presidency with 2 years and the previous and future presidents and the representatives from different regions to take part in the managing board, were added to the regulations at the 1st extraordinary General Assembly which was held in 2004. By this way, important steps were taken for the features of the foundation such as being an institute and participator.

    In General Assembly of National Cancer Congress (UKK), which is the most important cancer congress, which was done in 2003, it is decided to organize National Cancer Congresses with the joint consortium of Medical Oncology, Radiation Oncology and Pediatric Oncology Foundations. Since this year, National Cancer Congresses were done by these three foundations, biyearly.

    Our society has come to the phase of institutionalization in 2004-2006 period in which Haluk Onat has presided. During this period, Competence Board, Education and Coordination Board, Regional representative guidelines were formed and these councils were added to the regulations of the society at the second extraordinary General Assembly which was done in 2005. The specialist representatives, subspecialty representatives, regional representatives of our society have begun to be selected and present in society councils since 2005.

    Law consultancy, institutional web site services have been started during this period, have been improved by the contributions of the Managing Board members of the following periods and still continuing their activities. The first competency examination was done in 2005 and the certificates of competency were given to the members in the teaching staff. Our members still benefit from the research, publication and support programmes which have been produced during this period.

    The first Medical Oncology Congress that was organized by our society was done in 2006 and continues to be done biyearly. The joint symposiums with the collaboration of the Turkish and Greek colleagues have been started to be done since 2005. With the contributions of our society, ESMO congress which has been organized by European Medical Oncology Society with the highest level of participation until that year was organized in Istanbul in 2006.

    The number of members has increased to 222 during 2006-2008 period that was presided by Idris Yücel. Several national and international joint symposiums, courses and educational activities have continued. The decoration of the head office in Istanbul has been completed and opening has been done in May 2007. During this period studies for media activities were started and publications related to cancer were followed and media meetings were organized. The collaboration with the Greek colleagues which has been started during the previous period has been improved by participation of the other Mediterranean countries and converted to a regular organizational structure named as Mediterranean Multidisciplinary Oncology Forum. The “Medical Oncology Society Commercial Enterprise” has been founded in accordance to the developing needs of the society, during 2008-2010 period that was presided by Ahmet Demirkazık. During this period, regular educational programmes have been started named as Medical Oncology School by forming Medical Oncology Core Education Program. These programes still continue within the scope of Postgraduate Training Courses and broadcasted in our web site.

    ‘’Best of ASCO’’ meetings are regularly done institutionally by the collaboration with ASCO since 2010. “Interdisciplinary Uro-oncology” meetings have been started together with Turkish Radiation Oncology and Uro-oncology Societies and still continue.

    Reports were prepared about the topics such as “The state of Medical Oncology in Turkey”, “Our problems and rotation problem in Universities", “The problems in Subspecialty Compulsory service and recommendations for solution offer" and interviews were done with the President of Grand National Assembly of Turkey and the President of Health Commission. Interventions were started in medical oncology clinics which were chosen as pilot centers in Turkey, with the aim of institutionalization of training nursing within the scope of the Project of Education of Medical Oncology Training Nurse.

    The presidency of our society during 2010-2012 was done by Suayib Yalcın. The number of members of the society has increased to 393 during this period. The request of the Medical Oncology Society for using the word “Turkish” at the beginning of the name was accepted by the decision of the “Ministry of Internal Affairs” dated in 31.08.2012 and the name of our society was accepted as Turkish Medical Oncology Society. Our society has become member of ‘’Union for International Cancer Control’’ UICC in 2012. Upon our web site it has become possible to reach international publications. Two containers were donated to the Van State Central Training and Research Hospital due to Van Earthquake.

    The constitution of the discipline committee and the Young Oncologist Committee has been decided during this period and it has been added to the regulations in ordinary General Assembly which was done in 2012. "Young oncologists’’ has been accepted by ESMO and reached to an international status. Presently a team which was formed by Young Oncologists translate “ESMO cancer guidelines for the patients” to Turkish and when it was completed it will be present in Turkish, in web page of ESMO.

    Since the foundation, our society has exerted effort for personal rights about the problems of doctors and medical oncologists and the laws, both by oneself and with other societies and Turkish Medical Association and still continues activities in this topic.

    All institutions of our society which were constituted in various periods continue their studies and the training activities that the society performs such as courses, congresses, research, project, support for foreign education, web site activities are conducted regularly without interruption. It will continue to develop and to institutionalize more, with the contributions of our members and the future managing boards.
  • Values

    Democratic-participating
    We give importance to equality of opportunities by encouraging and providing active participation of our members and all other partners to our activities. We believe that participation of our members to the decisions that were taken and activities that were performed, underlie our success.

    Transparent
    In all our activities transparency is our main principle and we base on sharing with our members on this subject.

    Supportive- inclusive
    We support the efforts of all our members and partners in accordance to these principles. We present an incentive approach for all our members about participation to activities of the society.

    Objective– Egalitarian
    By avoiding biased behaviours, we take our decisions in accordance with the objective principles.

    True – reliable
    We conduct the relations between the society and our members based on the principle of honesty. We obey ethical standards in all relationships. We behave honest and give importance to the principle of mutual trust in relationships with our members, partners and other institutions.
  • Turkish Medical Oncology Society Regulations

    Name and head office of the society:
    Item 1 – The name of the society "Turkish Medical Oncology Society" is written as abbreviation, “TTOD”. It has no branch.

    The head office is in Istanbul. Address: Cumhuriyet Street No: 81, Flat 7 Apartment 7 Elmadag / ISTANBUL

    Aim of the society:

    Item 2 – The main aim for foundation of the society is to support and provide scientific and social development of “Medical Oncologists” and the people who practice “Medical Oncology Specialty Education” whose number is increasing in our country in each day, by assembling them under an occupational and social roof.
    For this purpose the society:
    a) organizes scientific meetings representing the developments in treatment and diagnosis of cancer, including Medical Oncology topics and makes contributions and make publications in this topic.

    b) performs studies for organization and standardization of medical oncology education and teaching in education and teaching institutions in our country and makes efforts for putting them into practice.
    c) makes scientific and technical collaborations in accordance with their aims, with the similar national and international scientific institutions that make research about medical oncology and tranfers related knowledge and publications to the members.
    ç) makes contribution to researches and organizations about the diagnosis, treatment of cancer and fight against cancer which are performed or will be performed in our country.
    d) takes legal action against people and institutions that advertise and trade the treatment methods that has no evidence of scientific effectiveness. Informs public opinion about the treatment of cancer, tries to prevent the abuse of the patient and patient’s relatives.
    e) consults the public and private treatment institutions which were founded or will be founded, about the topics related to medical oncology, makes contribution for increasing the level of medical oncology practices.

    The society is involved in protection of socio-economic rights of the members and the relevant assistant staff against the institutions regarding this matter and to increase the standards of social life.

    Safe harbors:

    Item 3 – The society has the right and the authority to use “Turkish” by the decision of Ministry of Internal Affairs General Directorate of Societies dated in 06.09.2012 and numbered as 3345.

    Founder members:

    Item 4 – The founders of the society are shown below according to the alphabetical order.

    Metin ARAN, MD, Associate Prof. Nationality: Republic of Turkey, Occupation: Medical Doctor, Address: Turkish anti-cancer foundation, Oncology Center, Levent-Istanbul

    Bülent BERKARDA, MD, Prof. Nationality: Republic of Turkey, Occupation: Medical Doctor,

    Address: Chancellor of Istanbul University, Istanbul.

    Evin BÜYÜKÜNAL, MD, Prof. Nationality: Republic of Turkey, Occupation: Medical Doctor,

    Address: Cerrahpasa Medical Faculty Medical Oncology Department, Cerrahpasa -Istanbul.

    Haluk ONAT, MD, Prof. Nationality: Republic of Turkey, Occupation: Medical Doctor,

    Address: Istanbul University Oncology Institute, Capa -Istanbul.

    Süheyla SERDENGECTI, MD, Prof. Nationality: Republic of Turkey, Occupation: Medical Doctor,

    Address: Cerrahpasa Medical Faculty Medical Oncology Department, Cerrahpasa -Istanbul.

    Erkan TOPUZ, MD, Prof. Nationality: Republic of Turkey, Occupation: Medical Doctor,

    Address: Director of Istanbul University Oncology Institute, Capa -Istanbul.

    Necdet USKENT, MD, Prof. Nationality: Republic of Turkey, Occupation: Medical Doctor,

    Address: Gülhane Military Medical Faculty Medical Oncology Department, Haydarpasa Istanbul.

    Members of society:

    Item 5 –The members of the society that meet the conditions which were proposed in the legislation of foundations and adopt the aims and the principles of the society are two types as the original and honorary members.

    a) Original members: are composed of "Medical Oncologists" and people who are having "Medical Oncology Specialty Education". The candidates that fill the membership form and apply with the recommendations of at least two original members, are accepted to the membership with the decision of the Managing Board.

    b) Honorary members: are selected among the individuals and the institutions that make contribution to the aims of the foundation and among the individuals that help development of medical oncology with the proposal of the Managing Board and approval of the General Assembly. The honorary members could join to all kinds of meetings, however they have no right to vote. The continuation of the original membership is provided by regular payment of the annual fees. The amount of the fees are decided according to the (m. 20/a) judgments.

    Leaving and being removed from the membership:

    Item 6 – Each member has the right to leave the society as long as they notify in written.
    When the resignation letter of the member reaches the Managing Board, the leaving procedures are accepted to be ended. Leaving the membership doesn’t finish the cumulated debts. The members that doesn’t obey the aims and regulations of the society, that doesn’t pay the fees for two years despite the warning of the Managing Board, that behave so as to undermine the professional dignity and the members who lost the civil rights are removed from the membership with the proposal of the Managing Board and the decision of the General Assembly. The individuals that leave or being removed from the society are erased from the member registry and could not put in a claim for the assets of the society.

    Foundation bodies

    Item 7 – The foundation bodies are below:
    a) General Assembly
    b) Managing Board
    c) Supervisory Board
    d) Competency Board
    e) Regional Representatives
    f) Discipline Committee
    g) Young oncologist Representative Board


    General Assembly:

    Item 8 – General Assembly is the most executive decision making body of the society, which is composed of original members. They “ordinary” meet in council once in two years within December at a place and at a time which are determined by the Managing Board. If the majority of the original members could not be provided at the first meeting, the majority is not necessary for the second meeting that would be held within a week. Besides, in situations which are found to be necessary by the Managing Board or the Supervisory Board or with the written request of one fifth of all original members, they could meet in council extraordinarily within 30 days with the request of the Managing Board. The voting of the members in General Assembly belong to the participating member and it is a single vote. The member should vote personally. Deputation could not be given.

    General Assembly Meeting Principles

    Item 9 – The below principles are carried out in General Assembly Meetings.

    a) The members of the General Assembly attend the meeting by signing to the names present in the “General Assembly Members List” which was arranged by the Managing Board. According to the signed list, the number of members participating the General Assembly, the quorum and the quorum of decision are determined with a written report which is signed by the president of the executive board and secretary member.

    b) The general assembly is opened by the President or vice president of the executive board after the general secretary reads the written report which mention that the majority is provided and one council president and two council secretaries are chosen to conduct the General Assembly.

    c) The items in the agenda are discussed in General Assembly. However it is mandatory to put the items which are requested to be discussed in written form by at least 1/10 of the participating members and which are related to the present agenda items to the agenda.

    ç) Unless decided contrarily in the General Assembly, the voting is done openly. In open voting, the method that is indicated by the president of the General Assembly, has been conducted. In case of conducting secret voting, the voting papers which are sealed by the chairman of the meeting, are put into an empty container after the members do the necessary and the result is determined by open inventory after the end of voting.

    d) The quorum in the General Assembly is the absolute majority of the members participating to the General Assembly. However, the quorum is needed in the items related to the abolishment of the society with the change in charter and the voting is done openly.

    e) The reports of the Managing and Supervisory Boards are examined, discussed, accepted or refused.

    f) The forecast budget and the activity programme of the future period is determined.

    g) Additional roles and authorities on the necessary topics are given to the Managing Board.

    h) The recommendations for removing from the membership are examined and were settled.

    ı) The changes in the regulations which are found to be necessary are done.

    i) When necessary, the decision for abolishment of the society is made. j) The members of the Managing and Supervisory Boards and the associated members are chosen.

    k) Within 30 days following the General Assembly, the lists of the original and the associated members which were chosen to the Managing and the Supervisory Board and to the other bodies of the society are reported to the local authority.

    Managing Board:

    Item 10 – The Managing Board is composed of 9 original and 5 associated members. The General Assembly choses the vice president and the other members of the Managing Board separately by secret voting. At least three of the original members of the Managing Board are selected outside the center. The selected vice president is assigned as the president for the next period. If there is no vice president which was selected by the General Assembly in the previous period, a president is selected also. The same person could not be president for two periods one after the other. The president becomes the ordinary member of the Managing Board during the second period after the period that he is selected, he could not be selected to the Managing Board again unless two periods pass following the end of the ordinary membership.

    10.1 In case of equality as a result of counting the votes, the candidates that take equal vote, perform the tasks of the vice president, president and the ordinary member of Managing Board by turns according to the turn that they decide by themselves and with equal periods within the period.

    10.2 The selected Managing Board choose the general secretary and the accountant between themselves. The Managing Board could always be invited to the meeting as long as informing all members. They get together when one more than half of the total number of members become ready. The decisions are made with the absolute majority of the total number of members participating the meeting.

    10.3 If there is vacancy within the ordinary member of Managing Board due to reassignment or other causes, it is mandatory to invite the associated members to the task according to the order of majority of votes that they take in the General Assembly.

    10.4 The Managing Board membership of the member that doesn’t participate to the meeting of the Managing Board for three times one after the other and the associated member that has taken the highest vote is assigned instead.

    The tasks of the Managing Board:

    Item 11 – The Managing Board is responsible to carry out all kinds of society works within the limits of the Regulations about foundations and the charter.

    For this purpose:

    a) carries out the procedures related to the society members.
    b) prepares the budget of the society related to the next period and provides implementation of the budget, spends the necessary expenses.
    c) employs wage personnel to provide the society works when it is necessary.
    d) makes the correspondances, keeps the necessary accounts.
    e) organizes a widespread scientific meeting at least once in every year.
    f) performs monthly scientific meetings.
    g) puts all activities into report form, makes preparations for General Assembly and presents them to approval in General Assembly
    h) makes invitation for Extraordinary General Assembly meeting when it is necessary.

    Supervisory Board:

    Item 12 – Three original and three associated members are selected by the General Assembly with secret vote. If there is vacancy within the ordinary member of Supervisory Board due to resignment or other causes, it is mandatory to invite the associated members to the task according to the order of majority of votes that they take in the General Assembly. It controls the accounts and the registries of the society and the accordance of the procedures and the activities to the legislation with intervals not more than one year at the latest and presents the results of the supervision as a report, to the Managing Board and to the General Assembly when they gather. In necessary situations, it makes invitation for extraordinary General Assembly meeting. Besides it uses the other tasks and the authorities provided by the legislation.

    The way of internal audit of the society:

    Item 13 – Related to actualizing the aim indicated in the charter of the society, the way of internal audit of the society:
    a) regulation of the indicated organs, subsidiary organs, tasks, authorities and responsibilities,
    b) providing and maintaining a consensus between the members,
    c) putting rules for the way of collecting the incomes of the society and spending the expenses,
    ç) depending on the reports of the specialists, to put objective measures and values about the topics such as activity features, social welfare and so forth and to practice these,
    d) for solution of all necessary topics, it is prepared by the regulations and instructions that are decided by the General Assembly.

    Competency Board:

    Item 14 – The competency board is composed of 7 members who are medical oncologists for at least 7 years and who are determined by the Managing Board of the Medical Oncology Society. One of the members is charged to provide coordination with the Managing Board of the society, among the members of the Managing Board of the society. The members of the Competency Board couldn’t take in charge for more than two periods one after the other. The regional representatives could be candidate for the Competency Board. If they are selected, they should leave the regional representative. The Competency Board is responsible against the Managing Board of the society. When it is necessary, the Competency Board could request from the Managing Board to form study subgroups.

    The tasks of the Competency Board members:

    Item 15 -
    a) performing studies to provide the national adequacy in the field of medical oncology,
    b) determining the dates of the competency exams, the amount of entrance fee and to announce these at the beginning of the year,
    c) to confirm the examination lists,
    d) to announce the results of the exams and to confirm the documents,
    e) to present semiannual study reports to the Managing Board

    Regional representatives:

    Item 16 – At least five regional representatives that are determined by the Managing Board are present. The regional representatives are selected by the society members of that region. It is obligatory to be a member of the society to be selected as a regional representative.
    16.1 The regional representatives participate to the meetings of the Managing Board that they want to attend or that they are invited, but they have no right to vote.
    16.2 The period of office is 2 years that will continue till the next General Assembly Meeting. The elections are done within 2 months following the ordinary general assembly that is done biyearly. If extraordinary general assembly gathers and the members of Managing Board changes within this period, the regional representatives are selected again.

    The tasks of the regional representatives:

    Item 17 -
    a) To be a member of Scientific Coordination Committee together with the Managing Board and to organize scientific programme in the Medical Oncology Congresses that the society organize,
    b) to be a member of subcommittee, that organize courses and credit the activities, which is a part of TMOS Education Planning and Coordination Committee,
    c) to provide interaction between the medical oncologists in their regions and the Managing Board of the Society, to perform activities in their regions and to announce the activities,
    d) to provide the membership of the present medical oncologists and the individuals who are in specialty education for medical oncology in their regions,
    e) to carry out activities related to the solution and announcement of the problems about the medical oncology in their regions.

    Discipline Committee:

    Item 18 – The discipline committee is composed of 5 members that are selected by the Managing Board. The period of office is two years. They select a president among themselves. In addition to the conditions of ordinary membership that is present in the charter, it is obligatory to have experience in the field of medical oncology for at least 15 years and to be above 45 years old. The discipline committee have the authority to take all precautions for protection of professional dignity and even to give suggestion to the Managing Board for removal of a member from the society if necessary.

    Young Oncologist Group:

    Item 19 -

    19.1. Aim
    To provide Young Medical Oncologists to have right to comment on management of the Turkish Medical Oncology Society, to adopt their problems, to provide organization of activities such as international and national education, research, scholarship.

    19.2. Formation of the group:
    The individuals who are continuing to their subspecialty training in medical oncology or the individuals who completed their subspecialty training but who are below 40 could be members of the group.

    19.3 Young Oncologist Representative Committee:
    The selected specialists and the subspecialty representatives from the Young Oncologist Representative Committee. The subspecialty assistants select the assistant representatives and the specialists aged below 40 select the specialist representatives according to the number and the method that is determined by the Managing Board of TMOS. The distribution of the representatives are determined according to the present number and needs at the time of election, by the decision of the Managing Board. The Young Oncologist Representative Committee represent the Young Oncologist Group in the Managing Board of TMOS.

    Incomes of the society:

    Item 20 – The incomes of the society are formed by these:

    a) Annual fees of the ordinary members: the membership fee is 20,00 TL annually. It is determined by the General Assembly.
    b) The public reliefs and the financial aids and the donations which are done by the natural and legal persons at own request.
    c) the incomes that are obtained from the activities related to the works and services that are relevant to the aim of the society (congress, seminar, symposium etc.)
    d) incomes obtained from social activities (ball, food, tea, trips, concerts etc.)
    e) the incomes obtained from the commercial enterprises, companies which are formed to obtain income to realize the aims and the services,
    f) the incomes obtained from the charity collections by putting case and box to certain localizations, by opening accounts in banks, with charity stamps, by organizing raffles, cultural programmes and exhibitions, sport programmes, trips and entertainments in accordance to the judgments of the law of charity collection,
    h) Other incomes

    Income-expenditure method of the society:

    Item 21 – The incomes of the society are collected with the “proof of receipt”. In case of collection of the incomes of the society by the banks, the receipt or account abstract that is formed by the bank is accepted as the “proof of receipt”. The expenditures of the society are performed by vouchers such as bill, retail sales receipt, self-employment invoice. However for the payments of the society which are found within the 94th item of the “Income Tax Law”, note of expenses are formed according to the judgments of “Tax procedure law”, and for the payments which are not found in this context, “Expense voucher” are arranged.

    The free property and service delivery to the individual, institution or foundation by the society are done by “Public relief Delivery Notice”. The free property and service delivery to the society which will be done by the individuals, institutions or foundations are accepted with “Public Donation receipt proof”.
    The proofs of receipts which will be used in collection of the incomes of the society are provided by the official authorities or are printed with the decision of the Managing Board.

    During printing and controlling the proofs of receipts, receiving them from the printing house, recording them to the registry, handover between the new and old accountants and the use of the proof of receipt by the individual or individuals on behalf of the society, the delivery of the collected incomes, the action is taken according to the related judgments of the Society Regulations.
    It is obligatory to withhold the registry and documents related to the income and expenditures for at least a period that is indicated in the law.

    The registries that should be held:

    Item 22 – A registry is held in the society based on the operating account. However, in case of exceeding the amount indicated in the regulations, the registry is held based on balance sheet beginning from the subsequent accounting period. In case of passing to balance sheet basis, if the amount decreases to the above mentioned amount in two accounting periods, it is possible to turn to operating account. Without adhering to the above mentioned amount, with the decision of the Managing Board, registry could be held based on balance sheet.

    In case of opening the commercial enterprise of the society, an additional registry is held for each commercial enterprise according to the judgments of Tax Procedure Law.
    22.1. The registries that will be held in the account of the enterprise is as follows:

    1- Decision registry
    2- Member registry
    3- Document registry
    4- Proof of receipt registry
    5-Inventory registry
    6- Operating account registry

    22.2. During balance sheet, in addition to the registries in the 1st and 4th embankments of 22.1.1st item; remuneration, ledger and inventory registries are held.

    The way of indebtedness of the society:

    Item 23 – To reach the aim and to conduct the activities, the society could become indebted with the approval of General Assembly and decision of the Managing Board in case of need. This indebtedness could be related to purchase of goods and services on credit or by cash. However this debtedness should not be in such amounts that couldn’t be met with the income sources of the society and that could put the society to payment difficulty.

    Help and collaboration:

    Item 24 – Save for the law enforcements numbered as 5072, related to the relations of the Societies and the Foundations with the public institutions and foundations, the society could take financial support from the societies that have similar aims such as the employee’s and the employer’s unions and occupational societies and could provide financial support to the above named institutions. Save for the above named law enforcements, the society could conduct common projects with the public institutions and foundations. In these projects, the public institutions and foundations could make contribution to the society in cash and in kind maximally at a rate of fifty percent of the cost of the projects.

    Taking welfare from abroad:

    Item 25 – As long as informing the local authorities previously, the society could take welfare in cash and in kind from the individuals, institutions and foundations who are abroad. It is obligatory to take the welfare in cash through banks.

    Change in charter:

    Item 26 – The changes in charter could be done with the decision of the General Assembly. For making a change in charter in the General Assembly, the majority of at least 2/3 of the members who have the right to attend the General Assembly is necessary. In case of postponement of the meeting due to not achieving the majority, at the second meeting the majority is not needed. However the number of members attending this meeting could not be less than two fold of the total member number of the managing and discipline boards

    The majority for decision that is necessary to make change in charter is 2/3 of the votes of the members that attend the meeting and who have the right to vote. The voting for making change in charter in the General Assembly is done in open manner. The proposal of at least 1/10 of the members that are ready in General Assembly is necessary to make changes in charter that are not found in the agenda of the General Assembly.

    Abolishment of the society:

    Item 27 –The General Assembly of the society could always decide abolishment of the society. For the General Assembly to decide abolishment of the society, according to the charter, at least 2/3 of the society members who have the right to attend the General Assembly should be ready in the meeting. If the majority could not be achieved in the first meeting, the members are invited to the second meeting.

    Regardless of the number of members in the second meeting, the abolishment could be discussed. The decision related to abolishment should be given by 2/3 majority of the members who are ready in the meeting. When the decision of abolishment is given, the abolishment of the society is reported in written form, to the highest civilian authority within seven days by the Managing Board. When the decision of abolishment is given by the General Assembly, the last managing board serve as the liquidation board. In case of abolishment, all goods, Money and rights of the society are transferred to Turkish Red Crescent.

    Other judgments:

    Item 28 – The related items and judgments of the “law and legislation of foundations” and “Turkish civil code” are carried out for the topics and the judgments in which the details could not be determined within this legislation.

    Validity:
    Item 29 – These changes in charter are accepted in the meeting of Ordinary General Assembly dated in 23/12/2012 and validated at the same date.
    PRESENT BOARD MEMBERS
    Pınar SAIP, MD
    Ahmet OZET, MD
    Suayib YALCIN, MD
    Hüseyin ABALI, MD
    Sercan AKSOY, MD
    Cem BORUBAN, MD
    Mahmut GUMUS, MD
    Alper SEVINC, MD
    Fulden YUMUK, MD
  • Medical Oncology Specialty Students-Education Programme

    I) BASIC SCIENTIFIC PRINCIPLES

    CANCER BIOLOGY
    Educational objectives:

    1. Normal cell biology
    2. Main steps in carcinogenesis
    3. Gene structure
    4. Gene expression
    5. Cell cycle
    6. Interaction between therapy and cell cycle
    7. Tumor cell kinetics
    8. Tumor cell proliferation
    9. Programmed cell death
    10. Balance between cell death and cell proliferation
    11. Molecular techniques
    12. PCR
    13. Chromosomal analysis
    14. Other techniques of molecular and basic cell biology

    TUMOR IMMUNOLOGY
    Educational objectives:

    1. Cellular and humoral components of immune system
    2. Regulatory effects of cytokines on immune system
    3. Interaction-communication between tumor and host immune systems
    4. Tumor antigenicity
    5. Immune system mediated tumor anti-tumor cytotoxicity
    6. Direct effect of cytokines on tumor cell

    ETIOLOGY, EPIDEMIOLOGY, SCREENING and DEFENSE

    Educational objectives:

    1. Etiological role of genetic and environmental factors in oncogenesis
    2. Epidemiological factors and identifiers of the diseases
    3. Basic principles of screening and risk evaluation
    4. Sensitivity and specificity of tests
    5. Cost/benefit ratio
    6. Basic principles and indications of genetic screening and consultation
    7. Primary, secondary and tertiary protection in cancer development

    CLINICAL STUDY and STATISTICS
    Educational objectives:

    1. Planning of a clinical study
    2. Phase I study
    3. Phase II Study
    4. Phase III Study
    5. Ethical aspects in study planning
    6. Regulatory aspects in study planning
    7. Legal aspects in study planning
    8. Evaluation criteria of the response to treatment
    9. Evaluation of life quality
    10. Basics of statistics
    11. Evaluation and grading of toxicity
    12. Role and function of institutional and central ethical committees
    13. Patient informed consent
    14. Basic principles in writing the applications to research support
    15. Institutions giving research support
    16. Treatment cost and cost-effectiveness analysis
    17. Basic principles in preparation of abstract
    18. Basic principles in preparation of oral and video presentations
    19. Basic principles in writing article
    20. Scientific value of the published articles and evaluation of their introduction to daily practice (criticizing)
    21. Relations with international study groups

    II) BASIC PRINCIPLES IN TREATMENT AND MANAGEMENT OF MALIGNANT DISEASES

    PATHOLOGY/LABORATORY/MOLECULAR BIOLOGY
    Educational objectives:

    1. Examination of the biopsy material and surgical specimen by the pathologist
    2. New pathology techniques
    3. Laboratory tests
    4. Serum tumor markers
    5. Cell membrane markers
    6. DNA markers

    STAGING PROCEDURES
    Educational objectives:

    1. Tumor-Node-Metastasis staging system
    2. Indications for clinical staging procedures
    3. Indications for radiological procedures
    4. Indications for nuclear medicine imaging procedures
    5. Evaluation of the response to treatment

    TREATMENT
    Surgery
    Educational objectives:

    1. Indications and contraindications to surgery
    2. The role of surgery in staging, cure and palliation
    3. Indications for organ protective surgery
    4. Principles in arrangement of surgery and other treatment modalities
    5. Risks and benefits of adjuvant surgery to definitive surgery and radiotherapy and/or to other treatment modalities
    6. Postoperative complications

    Radiation oncology
    Educational objectives:

    1. Principles of radiation biology
    2. Radiotherapy indications as curative treatment
    3. Radiotherapy indications as palliative treatment
    4. Principles of treatment planning and dosimetry
    5. Indications for the alignment of surgical tratments and/or anti-cancer drugs along with radiotherapy.
    6. Acute and late side effects

    Anticancer drugs
    Educational objectives:

    1. Indications and objectives in primary treatment of malignant diseases
    2. Indications and objectives in rescue therapy of recurrent malignant diseases
    3. Effectiveness in neoadjuvant therapy
    4. Effectiveness in concurrent treatment
    5. Effectiveness in adjuvant treatment
    6. Indications as radiation sensitizer
    7. Importance of delays in dose and treatment
    8. Evaluation of associated medical diseases (comorbidities) of the patients
    9. Pharmacokinetics
    10. Pharmacogenomics
    11. Pharmacology of various agents
    12. Toxicity profile of each anticancer drug and their long-term damages
    13. Regulations in dose and treatment schedule in organ dysfunctions

    Biological Treatment
    Educational objectives:

    1. Indications for biological treatment (including cytokine and hematopoietic growth factors)
    2. Specific side effects and their management
    3. Chemotherapy combinations
    4. Monoclonal antibodies
    5. Tumor vaccines
    6. Cellular treatment
    7. Gene-directed treatments

    Supportive and palliative treatment”
    Educational objectives:

    1. Indications for supportive treatment
    2. Limitations of supportive treatment
    3. Side effects of supportive treatment
    4. Indications for palliative treatment
    5. Termination of life support
    6. How can it be used in clinical applications?

    Supportive Treatments
    Educational objectives:

    1. Etiology of nausea-vomiting
    2. Pharmacology and mechanism of action of antiemetic drugs
    3. How should antiemetic drugs be used in daily applications

    Infection and neutropenia
    Educational objectives:

    1. Diagnosis and management principles of infection and neutropenic fever
    2. Treatment and prevention of infections
    3. Indications of hematological growth factors

    Anemia
    Educational objectives:

    1. Indications and complications of erythrocyte suspension transfusions
    2. Preparation of erythrocyte suspensions
    3. Indications of erythropoietin

    Thrombocytopenia
    Educational objectives:

    1. Indications of thrombocyte suspension transfusions
    2. Complications of thrombocyte transfusions
    3. Preparation and administration of thrombocyte suspensions

    Bone marrow and peripheral progenitor (stem) cells
    Educational objectives:

    1. Obtaining and cryopreservation of bone marrow and peripheral progenitor cells

    Organ Protection
    Educational objectives:

    1. Organ protection methods and treatment
    2. Indications and side effects of various organ protective agents
    3. Fertility preservation techniques

    Mucositis

    Educational objectives:

    1. Differentiation of infectious mucositis and anticancer drug-related mucositis
    2. Pain therapy and topical anesthetics

    Malignant effusions
    Educational objectives:

    1. Symptoms, signs and treatment of ascites
    2. Symptoms, signs and treatment of pleural effusions
    3. Symptoms, signs and treatment of pericardial effusions
    4. Treatment of effusions with paracentesis

    Extravasation
    Educational objectives:

    1. Prevention of extravasation
    2. Diagnosis of extravasation
    3. Treatment of extravasation

    Oncological emergencies
    Educational objectives:

    1. Identification of the clinical conditions that require emergent intervention (EX: spinal cord compression, pericardial tamponate etc.)
    2. Appropriate approaches in diagnostic tissue sampling in cases with the suspicion of cancer
    3. Acute treatment
    4. Chronic treatment

    Paraneoplastic syndromes
    Educational objectives:

    1. Remote effects of malignancies
    2. The malignancies commonly associated with paraneoplastic syndromes
    3. Treatment of syndromes

    Feeding Support
    Educational objectives:

    1. Enteral feeding support
    2. Parenteral feeding support
    3. Complications of enteral feeding
    4. Complications of parenteral feeding

    Palliative care and terminal care
    Educational objectives:

    1. Evaluation of the localization and severity of pain
    2. WHO’s step-wise treatment in pain
    3. Pharmacology and toxicity of opioids and other analgesics
    4. Management of cancer pain
    5. Recognition of invasive palliative interventions and guidance

    Other symptoms
    Educational objectives:

    1. Palliation of symptoms of respiratory system
    2. Palliation of symptoms of gastrointestinal system
    3. Palliation of symptoms
    4. Symptoms of skin and mucosa
    5. Anorexia and cachexia
    6. Dehydration
    7. How to approach to symptoms of terminal period?

    Communication
    Educational objectives:

    1. Communication with the patient and family
    2. Informing about bad news
    3. How to behave in difficult conditions?
    4. Other health personnel (nurse, social worker, caregiver, psychologist etc.)

    Rehabilitation
    Educational objectives:

    1. Role of physical therapy especially in postoperative situations
    2. Role of occupational therapy
    3. Role of speech therapy
    4. Role of swallowing therapy

    III) DIAGNOSIS, TREATMENT AND MANAGEMENT OF CANCERS

    HEAD-NECK CANCERS
    Educational objectives:

    1. Physical examination of head-neck
    2. Risk factors in head-neck cancers
    3. Natural course of head-neck cancers according to localization
    4. Staging
    5. Panendoscopy
    6. Surgery and/or radiotherapy as definitive treatment
    7. Role of chemotherapy
    8. Role of palliation in advanced disease
    9. Organ protection
    10. Long-term management of the patients
    11. Secondary cancer risk

    LUNG CANCER and MESOTHELIOMA
    Educational objectives:

    1. Risk factors in lung cancer development
    2. Risk factors in mesothelioma development

    Small cell lung cancer
    Educational objectives:

    1. Multimodal approach in limited disease
    2. Role of chemotherapy in advanced disease
    3. Indications for central nervous system treatment

    Non-small cell lung cancer
    Educational objectives:

    1. Inoperability criteria
    2. Staging with surgical and nonsurgical techniques in localized disease
    3. The value of surgery in localized disease
    4. The value of chemotherapy in localized disease
    5. The value of radiotherapy in localized disease
    6. The value of combined modality in localized disease
    7. The value of chemotherapy in palliation of advanced disease
    8. The value of radiotherapy in palliation of advanced disease

    Mesothelioma

    Educational objectives:

    1. Risk factors
    2. Criteria for surgical treatment
    3. The value of chemotherapy

    GASTROINTESTINAL CANCERS

    Esophagus Cancer
    Educational objectives:

    1. Risk factors
    2. Endoscopy indications in diagnosis
    3. Endoscopy indications in staging
    4. Indications for feeding support
    5. Combined modality treatment
    6. Role of palliative chemotherapy
    7. Supportive therapies

    Gastric cancer
    Educational objectives:

    1. Risk factors
    2. Role of surgery
    3. Role of combined modality treatment
    4. Role of palliative chemotherapy
    5. Supportive therapies

    Colon Cancer
    Educational objectives:

    1. Surgical staging
    2. Indications for adjuvant treatment in colon cancer
    3. Indications for adjuvant treatment in rectal cancer
    4. Role of chemotherapy in advanced disease
    5. Hereditary types of colon cancer and the way of invasion and management
    6. Risk factors
    7. Screening in colorectal cancers
    8. Chemoprevention
    9. Genetic tests

    Anal Cancer
    Educational objectives:

    1. Relation with HPV
    2. Role of combined modality treatment in organ protection

    Hepatobiliary cancer
    Educational objectives:

    1. Epidemiology
    2. Risk factors
    3. AFP in diagnosis, screening and evaluation of response
    4. Surgical indications in localized disease
    5. Role of systemic and intra-arterial chemotherapy

    Pancreas cancer
    Educational objectives:

    1. Risk factors
    2. Genetic
    3. Role of endoscopy
    4. Role of molecular diagnosis
    5. Role of surgery in curative and palliative treatment
    6. Palliative role of chemotherapy in advanced disease

    GENITOURINARY CANCERS
    Renal cell cancer
    Educational objectives:

    1. Diagnosis
    2. Paraneoplastic syndromes
    3. Curative role of surgery in localized disease
    4. Role of biological treatment in advanced disease

    Urothelial cancers
    Educational objectives:

    1. Risk factors
    2. Differences between localized and invasive diseases
    3. Predisposition to recurrence in transitional epithelial cell carcinoma
    4. Role of urine cytology in staging and follow-up
    5. Role of cystoscopy in staging and follow-up
    6. Role of intravesical treatment in superficial bladder cancer
    7. Role of surgery in early-stage invasive cancers
    8. Combined modality treatment
    9. Management of metastatic transitional epithelial carcinomas

    Penile Cancer
    Educational objectives:

    1. Role of HPV in etiology of penile cancers
    2. Role of combined modality treatment

    Prostate Cancer
    Educational objectives:

    1. Epidemiology
    2. Screening of prostate cancer
    3. PSA indications in screening and follow-up
    4. Importance of histological grade
    5. Role of observation in management of early-stage disease
    6. Role of surgery in management of early-stage disease
    7. Role of radiotherapy in management of early-stage disease
    8. Hormonal therapy in advanced disease
    9. Chemotherapy in advanced disease

    Germ Cell Tumors
    Educational objectives:

    1. IGCCG (International Germ Cell Collaborative Group) classification
    2. Use of tumor markers in diagnosis, prognosis and follow-up
    3. Role of surgery
    4. Role of radiotherapy
    5. Role of chemotherapy
    6. Combined chemo-radiotherapy in advanced disease

    GYNECOLOGICAL CANCERS
    Ovarian cancer
    Educational objectives:

    Hereditary predisposition in ovarian cancer 1. Role of surgical interventions in initial staging
    2. Role of surgery in initial treatment
    3. Role of surgery in systemic treatment
    4. Chemotherapy indications in localized disease
    5. Chemotherapy indications in advanced disease

    Uterus cancer
    Educational objectives:

    • Hormones and role of hormonal therapy in etiology of endometrium cancer
    • Curative role of surgery in early-stage disease
    • Role of radiotherapy in multidisciplinary approach to advanced disease
    • Role of chemotherapy in treatment of local disease
    • Role of chemotherapy in treatment of metastatic disease
    • Role of hormonal therapy in treatment of local disease
    • Role of hormonal therapy in treatment of metastatic disease

    Cervix Cancer
    Educational objectives:

    1. Risk factors in cervix cancer
    2. Staging on the basis of surgical option
    3. Staging on the basis of radiotherapy
    4. Role of chemotherapy in advanced disease

    Vulvar and Vaginal cancers
    Educational objectives:

    1. Development of vaginal clear cell carcinoma in females whose mother had used diethylstilbestrol during pregnancy
    2. Follow-up
    3. Treatment-management
    4. Curative surgery in early-stage disease
    5. Combined modality treatment in advanced disease

    Breast cancer
    Educational objectives:

    1. Interpretation of mammogram
    2. Interpretation of breast ultrasonography
    3. Interpretation of breast MRI
    4. Pathological and prognostic factors
    5. Factors affecting the choice of primary treatment (including receptor assay)
    6. Hormonal therapy in advanced disease
    7. Chemotherapy in advanced disease
    8. Indications for adjuvant therapy
    9. Role of elective chemotherapy regimes
    10. Importance of family history and genetic test and consultation

    Sarcomas
    Educational objectives:

    1. Factors facilitating development of primary bone sarcomas
    2. Pathological classification
    3. Indications for limb conservation and adjuvant chemotherapy
    4. Role of combined modality treatment

    Soft tissue sarcomas
    Educational objectives:

    1. Surgery in initial diagnosis
    2. Indications for limb conservation
    3. Role of chemotherapy
    4. Role of surgery
    5. Role of radiotherapy
    6. Specific medical therapy in gastrointestinal tumors

    SKIN CANCERS
    Melanoma
    Educational objectives:

    1. Risk factors
    2. Clinical appearance of primary melanoma and its precursor lesion, dysplastic nevus
    3. Differentiation of benign lesions and lesions having potentially malignant appearance in skin lesions
    4. The value of tumor depth and other prognostic factors in determination of prognosis
    5. Surgical interventions in diagnosis and curative resection
    6. Indications for biological treatment in adjuvant therapy
    7. Risks and benefits of chemotherapy in advanced disease
    8. Primary protection in melanoma
    9. Identification of the patients who have high risk for melanoma development and consultation

    Basal cell and squamous cell cancers
    Educational objectives:

    1. Clinical appearance of lesions
    2. Association with sunlight contact
    3. Long-term complications of cancer treatment

    ENDOCRINOLOGICAL CANCERS
    Educational objectives:

    1. Diagnostic procedures
    2. Treatment of endocrinological cancers
    3. Endocrinological cancer as a part of cancer syndrome due to specific genetic defects
    4. Role of anticancer drugs

    CENTRAL NERVOUS SYSTEM MALIGNANCIES
    Educational objectives:

    1. Surgical treatment of primary disease
    2. Role of surgery in metastatic disease
    3. Role of radiotherapy in primary disease
    4. Role of chemotherapy in primary disease
    5. Role of chemotherapy in metastatic disease

    CANCERS WITH UNKNOWN PRIMARY ORIGIN
    Educational objectives:

    1. Importance of histopathology of tumor
    2. Pathological analysis in guidance of diagnostic procedures
    3. Tumor markers in guidance of diagnostic procedures
    4. Recognition and differentiation of the conditions in which treatment could affect survival
    5. Palliative treatment

    HEMATOLOGICAL MALIGNANCIES
    Leukemia
    Educational objectives:

    1. Pathological techniques in diagnosis
    2. Molecular biological techniques in diagnosis
    3. Cytogenetic
    4. Immune-phenotyping
    5. PCR
    6. Current treatment recommendations and adaptation of these to adult population and elderly

    Acute leukemia and myelodysplasia
    Educational objectives:

    1. Risk factors for development of leukemia
    2. French-American-British (FAB) classification
    3. Effect of classification on prognosis and treatment
    4. Bone marrow transplantation
    5. Value of differentiation therapy
    Chronic leukemia
    Educational objectives:

    1. Peripheral smear
    2. Current therapeutic approaches
    3. Indications for bone marrow transplantation

    Lymphomas
    Educational objectives:

    1. Ann Arbor Staging classification
    2. World Health Organization (WHO) classification

    Hodgkin’s disease
    Educational objectives:

    1. Staging of Hodgkin’s disease
    2. Indications for surgical staging
    3. Radiotherapy in early-stage disease
    4. Chemotherapy indications in Stage II, III and IV
    5. Long-term complications of treatment
    6. Follow-up of the patients
    7. Indications for bone marrow transplantation in recurrent or refractory disease

    Non-Hodgkin’ lymphomas
    Educational objectives:

    1. Lymphomas related with HIV and immunosuppression
    2. Revised European-American Lymphoma (REAL) classification
    3. International prognostic factors (IPI)
    4. Role of chemotherapy
    5. The value of bone marrow transplantation in recurrent and refractory cases
    6. Different types of low-grade lymphomas (when is the treatment indicated, when is observation indicated)
    7. Role of radiotherapy
    8. Role of surgery
    9. Role of chemotherapy including monoclonal antibodies, in treatment
    10. Clinical features of high-grade lymphomas
    11. Role of intensive treatment in high-grade lymphomas

    T-cell skin lymphomas
    Educational objectives:

    1. Clinical appearance in different stages
    2. Importance of immunophenotyping in diagnosis
    3. Role of ultraviolet A and psoralen in initial treatment
    4. Role of radiotherapy in initial treatment
    5. Role of topical chemotherapy in initial treatment
    6. Palliative role of chemotherapy in advanced or refractory disease
    7. Palliative role of biological agents in advanced or refractory disease
    8. Palliative role of radiotherapy in advanced or refractory disease

    Plasma cell dyscrasias
    Educational objectives:

    1. How could plasma cell dyscrasias be differentiated from MGUS (Monoclonal Gammopathy of Unknown Significance
    2. Waldenström's macroglobulinemia
    3. Plasmacytoma
    4. Multiple myeloma
    5. POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes)
    6. Plasma cell leukemia
    7. Treatment indications in all situations

    AIDS-related malignancies
    Educational objectives:

    1. Relation of CNS tumors with AIDS and immunosuppression
    2. Treatment indications
    3. Increase in toxicity related to associated medical problems
    4. Prophylaxis and treatment of common opportunistic infections

    PATIENT EDUCATION
    Genetic consultation
    Educational objectives:

    1. Evaluation of the increase in cancer risk in the patient and patient’s family
    2. Principles of genetic screening and consultation

    Protection of health
    Educational objectives:

    1. Having consultation with the patient and his family about the cancers that could develop later
    2. Diet
    3. Smoking
    4. Alcohol
    5. Exposure to sunlight

    Long-term complications
    Educational objectives:

    1. Identification of long-term complications of each treatment modality

    Cancer risk developing due to treatment
    Educational objectives:

    2. AML after chemotherapy
    3. Sarcomas due to radiation

    Endocrinological function disorders
    Educational objectives:

    1. Hypothyroidism after neck radiation
    2. Sterility related to chemotherapy
    3. Chemopreventive precautions
    4. Follow-up interval and recommended tests
  • Organization Structure

  • General Assembly

    General Assembly (GA) mainly approves and revises the bylaws of the society and deliberates and decides the proposals. GA approves the society’s budget and financial reports. Another role of GA is to elect the president-elect and executive committee for 2 years.

  • Our Society

    Turkish Society of Medical Oncology was established in Istanbul in 1997. The society is one of the most important organizations specialized in a field in Turkey with experience and nationwide representation and it has wide connection with other international and national organizations. It is the major player in various training activities and research in oncology. All of the medical oncologists are members of the society. The society is an excellent source of reference and support between the other oncology based societies not only for its members but also for its multidisciplinary organisations and educational courses.

    Turkish Society of Medical Oncology organizes meetings and prepares reports for the government and Turkish Medical Associations. It has influence on the government established cancer care policy, press releases for important public cancer problems, and it organizes national and international meetings, for instructions and regulations against medical oncologists rights.
    The society also gives young oncologists the opportunity to go beyond the nation and get the global notion by encouraging and supporting them to attend international courses and take part in international research studies.
     

  • Status of Medical Oncology in Turkey


    In Turkey Medical Oncology is a 3-year subspecialty after 4 years of internal medicine training. Medical oncologists plan and give the systemic and palliative treatment of cancer patients, manage the toxicities of cancer therapies and the symptoms of cancer, follow and give support to cancer patients from the diagnosis to the end of life.

    Medical oncology has the leading position among the other disciplines of internal medicine in Turkey. There are 450 medical oncologists including fellows. Although there is a shortage of medical oncologists, the number is growing fast. Currently, most of the medical oncologists are in academic positions. Two hundred of medical oncologists work in university hospitals or in government training hospitals. There are 350 specialists with academic degree, and 100 fellows. Majority of these medical oncologists work at state universities or state hospitals. Private university hospitals and private hospitals have less numbers of medical oncologists, but the number they have is also increasing. Vast majority of medical oncology fellows get their training at university hospitals and the others have training at government hospitals. Every medical graduate have to do compulsory state service at some time in their career, so currently, the number of medical oncologists in compulsory service is 75.

  • Mission

    As a society our mission is to protect the rights of the medical oncologists, support the needs of the cancer care professionals, solve general problems of medical oncology, share the knowledge with medical oncologist, support researches and establish the cooperation between other specialities.

    The society is committed to advance the art, science, recognition and practice of oncology. Besides this, in order to insure a high standard of qualification of medical oncologist we promote education in oncology. As a society, we assure that all cancer patients have access to optimal treatments and minimum standard of care.

  • Prospects

    One of the prospects of our society is to improve the role of Turkish medical oncologist in fight against cancer. Another important one is to improve standards of undergraduate and postgraduate education and training. Our organization aim is to increase multidisciplinary collaboration and higher participation with the international cancer organizations.

    The society also remarks to increase support in cancer research. We are well aware that public is the most important actor and target in fight against cancer and therefore the society uses every single opportunity to increase the awareness of public about cancer.

  • Executive Committee

    Executive Committee (EC) has 9 members, including president, general secretary, president-elect, treasurer, secretary, past president and 4 members. EC meets every months, advices and deliberates the affairs of the society. Besides this, EC facilitates and executes the decisions for society. EC appoints the official society representatives and oversees and approves society activities.


    President
    Dr.Mahmut Gümüş
    Vice President
    Dr. Serdar Turhal
    Past President
    (25.12.2016-31.12.2017)
    Dr. Ahmet Özet
    Past President
    (01.01.2018-31.12.2018)
    Dr. Gökhan Demir
    General Secretary
    Dr. Ahmet Bilici
    Treasurer Dr. Yeşim Eralp
    Member Dr. İrfan Çiçin
    Member

    Dr. Mutlu Doğan

    Member

    Dr. Özlem Er

     
    Member Dr. İlhan Öztop

     

     

  • Committee of Honorary Members

    Committee of Honorary Members is a committee of 5 selected by the EC and stay on duty for 2 years. Prerequisite for being a member is 15-year experience in the field of medical oncology and being over 45 years. Main responsibility of this is to protect the honor of the profession. Physician-physician or any other second party and physician disputes shall be discussed and appropriate advices be given to the EC. These advices will be key to define the position of the TSMO in disputes and for possible disciplinary actions.

    President Dr. Süheyla Serdengeçti  
    Member Dr. Haluk Onat  
    Member Dr. Nilüfer Güler  
    Member Dr. Dilek Dinçol  
    Member Dr. Önder Berk  
  • Audit Committee

    Audit Committee has three main and 3 reserve members selected by the GA. Audit Committee’s mission is to review and assure compliance with policies and procedures relating to the conduct of financial and business affairs of the society.

    Dr. Necdet Üskent  
    Dr. Mustafa Yaylacı  
    Dr. Ögür Özyılkan  

  • Proficiency Board

    Proficiency Board is a nonprofit and financed by the association and makes independent decisions as defined in the instructions of the Proficiency Board.

    Proficiency Board Committee regulates Medical Oncology specialist education and decides adequacy criteria prepares the fellow report card and makes board examinations. Board Committee also certificates and re-certificates.

    The board has organized four written examination which is organized centrally in conjunction with national examination and evaluation center and two oral examinations by using objective structured clinical examination method.

     
    President Dr. Serdar Turhal Member Dr. Mehmet Artaç
    Member Dr. Hasan Şenol Çoşkun Member Dr. Bülent Karabulut  
    Member Dr. Berksoy Şahin Member Dr. Oktay Tarhan
    Member Dr. Fulden Yumuk Member Dr. Ozan Yazıcı  
  • Regional Representatives

    Regional Representatives ; Executive Committee decides the number of regional (not synonymous with geographical regions) representative positions (currently 5). Regional representatives are selected by the members of the society-defined regions and are on duty for 2 years.Regional Representatives ’s are free to attend the EC meetings.

    Tasks of Regional Representatives’s;
     

    Are natural members of the scientific committee of the Medical Oncology Congress of TSMO,  

    To organize the educational courses planned and proposed by EPOC,
     
      To be a connection line between the society and the medical oncologists working in their region, to make TSMO aware of local problems related with members or cancer care,

      To distribute the educational and scientific activities of their region among other society members,

      To promote membership of TSMO among medical oncology specialists & fellows in their region,

    Northwest Regional Representative Dr. İrfan Çiçin
    Northeast Regional Representative Dr. Güzin Gönüllü Demirağ
    Middle Regional Representative Dr. Bülent Yalçın
    Representative in the Western Region Dr. Yüksel Küçükzeybek
    Southeast Regional Representative Dr. Emin Tamer Elkıran

     

  • Education Planning and Organizing Committee

    Education Planning and Organizing Committee (EPOC) consists of a chairman, elected by executive committee, and five elected representatives from 5 different regions of Turkey (East, North, South, Middle and West). EPOC makes the education programs and cooperates with the Ministry of Health to organize the rotation and education programs for the fellows. Turkish Society of Medical Oncology has taken role in continuing medical education by organizing Medical Oncology School (MOS) is a 3-year core curriculum program based on ESMO and ASCO educational schedules. MOS holds courses at weekends, every two months. The aim of MOS is to standardize medical oncology fellowship education. We give education grants and support to the members who wants to education in other countries.
    President Dr.Yeşim Eralp  
    Central Regional Representative Dr. Bülent Yalçın  
    South and Southeast Regional Representative Dr. Emin Tamer Elkıran  
    North and Northeast Regional Representative Dr. Güzin Gönüllü Demirağ  
    Representative in the Western Region Dr.Yüksel Küçükzeybek  
    Marmara and the Northwest Regional Representative Dr. İrfan Çiçin  
    Specialist Representative,2013 Dr. Özgür Tanrıverdi  
    Specialist Representative, 2014 Dr.Yeşim Yıldırım  
    Young Oncologists Minor Assistant Representative Dr. Ozan Yazıcı  
    Young Oncologists Specialist Representative Dr. M.Akif Öztürk  
  • Pursuit of Crab (Turkey's Oncology History)

 

Türk Tıbbi Onkoloji Derneği

Kullanıcı Girişi

Şifremi Unuttum